XML 56 R41.htm IDEA: XBRL DOCUMENT v3.25.0.1
Summary of Significant Accounting Policies (Details) - V C N - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Oct. 31, 2023
Dec. 31, 2022
Dec. 31, 2024
Dec. 31, 2023
Summary of Significant Accounting Policies        
Additional consideration related to the achievement of certain milestones     $ 70,200,000  
Amount to be paid due to approval   $ 3,000,000    
Payment made after clinical trial $ 3,250,000      
Fair value of contingent consideration     7,000,000  
Fair value measurement, transfer in to level3     0 $ 0
Fair value measurement, transfer out of level3     0 0
Operating Expense        
Summary of Significant Accounting Policies        
Increase in operating expense     $ 699,000  
Decrease in operating expense       $ 660,000